CONSIDERING SARCLISA

Find out if SARCLISA could be appropriate for you

The following 7 questions will help you understand if you or your loved one could be a candidate for SARCLISA

SARCLISA is for the treatment of adults with relapsed refractory multiple myeloma who have received at least 2 prior treatments for multiple myeloma, including Revlimid® (lenalidomide) and a proteasome inhibitor (PI).

SARCLISA is given together with Pomalyst® (pomalidomide) and dexamethasone, or Pd.

No personal information will be requested or collected, and responses will be anonymous.

Please note that SARCLISA is only for people who are 18 years of age or older.

Question : 1

…been treated with at least 2 different medicines for multiple myeloma?

Yes
No
I don't know

Find out how SARCLISA was studied and see the results.

Discussion icon

Use the SARCLISA Conversation Starter to help you have an informed discussion with your doctor at your next appointment.

Download

Sign-up icon

Stay up to date with the latest
information about SARCLISA.

Sign Up

You Could Be A Candidate
background image Sarclisa-PI-based-logo

Based on your responses, you or your loved one 

could be a candidate for SARCLISA

Talk with your doctor to learn more

Your doctor will know if SARCLISA is an appropriate treatment option for you.

Have you or your loved one…

Your answer

1

…been treated with at least 2 different medicines for multiple myeloma?

Yes

2

…had multiple myeloma return after a prior treatment  

(commonly referred to as relapsed multiple myeloma)?

Yes

3

…had multiple myeloma not respond, or stop responding, to a current or prior 

treatment (commonly referred to as refractory multiple myeloma)?

Yes

4

…been treated with Revlimid® (lenalidomide)?

Yes

5

…been treated with a proteasome inhibitor (PI)?

I don’t know

6

…been diagnosed with impaired kidney function?*

Yes

7

…been diagnosed with asthma or  

chronic obstructive pulmonary disease (COPD)?*

No

Share these answers with your doctor and use

the attached Doctor Discussion Guide to help start the conversation.

callout-box

What is SARCLISA?

 

SARCLISA is a prescription medicine used in combination with pomalidomide and dexamethasone to treat 

adults who have received at least 2 prior therapies, including lenalidomide and a proteasome inhibitor, to 

treat multiple myeloma.
It is not known if SARCLISA is safe and effective in children.

Important Safety Information

 

Do not receive SARCLISA if you have a history of severe allergic reaction to isatuximab-irfc or any 

of the ingredients in SARCLISA (see the list of ingredients in full Prescribing Information).

Please see additional Important Safety Information on the following pages, and full 

Prescribing Information, including Patient Information.

*People with impaired kidney function, asthma, and COPD participated in the SARCLISA study.

1


background image Sarclisa-PI-based-logo

Important Safety Information (cont’d)

Before receiving SARCLISA, tell your healthcare provider about all of your medical conditions, including if you:

     

are pregnant or plan to become pregnant. SARCLISA may harm your unborn baby. You should not receive 

SARCLISA during pregnancy. 
   Females who are able to become pregnant should use an effective method of birth control during treatment 

and for 5 months after their last dose of SARCLISA. Talk to your healthcare provider about birth control methods 

that you can use during this time.

   Tell your healthcare provider right away if you think you are pregnant or become pregnant during treatment 

with SARCLISA.

     

are breastfeeding or plan to breastfeed. It is not known if SARCLISA passes into your breast milk. You should not 

breastfeed during treatment with SARCLISA.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter 

medicines, vitamins, and herbal supplements.
How will I receive SARCLISA?

  

SARCLISA will be given to you by your healthcare provider by intravenous (IV) infusion into your vein.

  

SARCLISA is given in treatment cycles of 28 days (4 weeks), together with the medicines pomalidomide 

and dexamethasone.

   — In cycle 1, SARCLISA is usually given weekly.
   — Starting in cycle 2, SARCLISA is usually given every 2 weeks.
   Your healthcare provider will decide how long you should receive SARCLISA.

  

If you miss any appointments, call your healthcare provider as soon as possible to reschedule your appointment.

  

Your healthcare provider will give you medicines before each dose of SARCLISA to help reduce the risk of infusion 

reactions (make them less frequent and severe).

What are the possible side effects of SARCLISA?
SARCLISA may cause serious side effects, including:

  

Infusion reactions. Infusion reactions are common with SARCLISA and can sometimes be severe.

   — Your healthcare provider will prescribe medicines before each infusion of SARCLISA to help decrease your 

risk for infusion reactions or to help make any infusion reaction less severe. You will be monitored for infusion 

reactions during each dose of SARCLISA.

   — Your healthcare provider may slow down or stop your infusion, or completely stop treatment with SARCLISA, 

if you have an infusion reaction.

   Tell your healthcare provider right away if you develop any of the following symptoms of infusion 

reaction during or within 24 hours after an infusion of SARCLISA:

—  feeling short of breath

—   chills

—  cough

—   nausea

     

Decreased white blood cell counts. Decreased white blood cell counts are common with SARCLISA and 

certain white blood cells can be severely decreased. You may have an increased risk of getting certain 

infections, such as upper and lower respiratory infections. 
Your healthcare provider will check your blood cell counts during treatment with SARCLISA. Your healthcare 

provider may prescribe an antibiotic or antiviral medicine to help prevent infection, or a medicine to help 

increase your white blood cell counts during treatment with SARCLISA.

Please see additional Important Safety Information on the next page, 

and full Prescribing Information, including Patient Information

2


background image Sarclisa-PI-based-logo

Revlimid is a registered trademark of Celgene Corporation. 

© 2020 sanofi-aventis U.S. LLC.    All rights reserved.    MAT-US-2001907    07/20

Important Safety Information (cont’d)

   Tell your healthcare provider right away if you develop any fever or symptoms of infection during 

treatment with SARCLISA.

     

Risk of new cancers. New cancers have happened in people during treatment with SARCLISA. Your

healthcare provider will monitor you for new cancers during treatment with SARCLISA.

     

Change in blood tests. SARCLISA can affect the results of blood tests to match your blood type. Your

healthcare provider will do blood tests to match your blood type before you start treatment with SARCLISA.

Tell all of your healthcare providers that you are being treated with SARCLISA before receiving

blood transfusions.

The most common side effects of SARCLISA include: 

     

lung infection (pneumonia)

     

decreased red blood cell counts (anemia)

     

upper respiratory tract infection

     

decreased platelet counts (thrombocytopenia)

     

diarrhea

These are not all the possible side effects of SARCLISA. For more information, ask your healthcare provider 

or pharmacist.

Please see full Prescribing Information, including Patient Information.

3


background image Sarclisa-PI-based-logo

Find out more by visiting SARCLISA.com.

Treatment with SARCLISA

• 

How will I receive treatment with SARCLISA?

  

• 

How will I know if SARCLISA is working?

• 

How will you monitor my results?

• 

What are the possible side effects?

Considering SARCLISA

• 

  

Is there a study that shows SARCLISA may work for my condition?

• 

Was SARCLISA studied in people like me?

• 

What were the study results for SARCLISA?

• 

Based on my treatment history, is SARCLISA an option for me?

• 

  

Is there a patient support program that may help with the cost of SARCLISA?

Talk with your doctor about SARCLISA

If you or your loved one is considering treatment with SARCLISA, the questions  

below can help you have a productive conversation with your doctor


background image

Notes and questions

Use this space to write down additional questions you may have 

or information you want to share with your doctor

New to SARCLISA

®

 (isatuximab-irfc)?

Sign up for updates at SARCLISA.com to get the latest information.

Already signed up?

For information about our patient support program, CareASSIST from Sanofi Genzyme, 
please call 1-833-WE+CARE (1-833-930-2273), Mon – Fri, 9 am - 8 pm ET,

or visit SanofiCareAssist.com/sarclisa.

© 2020 sanofi-aventis U.S. LLC.     All rights reserved.     MAT-US-2004871     07/20

You May Be A Candidate
background image Sarclisa-PI-based-logo

SARCLISA may be appropriate for you or your loved one

Talk with your doctor to learn more

Your doctor will know if SARCLISA is an appropriate treatment option for you.

Have you or your loved one…

Your answer

1

"

…been treated with at least 2 different medicines for multiple myeloma?

Yes

2

…had multiple myeloma return after a prior treatment  

(commonly referred to as relapsed multiple myeloma)?

Yes

3

…had multiple myeloma not respond, or stop responding, to a current or prior 

treatment (commonly referred to as refractory multiple myeloma)?

Yes

4

…been treated with Revlimid® (lenalidomide)?

Yes

5

…been treated with a proteasome inhibitor (PI)?

Yes

6

…been diagnosed with impaired kidney function?*

Yes

7

…been diagnosed with asthma or  

chronic obstructive pulmonary disease (COPD)?*

Yes

callout-box

Share these answers with your doctor and use

the attached Doctor Discussion Guide to help start the conversation.

What is SARCLISA?

 

SARCLISA is a prescription medicine used in combination with pomalidomide and dexamethasone to treat 

adults who have received at least 2 prior therapies, including lenalidomide and a proteasome inhibitor, 

to treat multiple myeloma.
It is not known if SARCLISA is safe and effective in children.

Important Safety Information

 

Do not receive SARCLISA if you have a history of severe allergic reaction to isatuximab-irfc or any 

of the ingredients in SARCLISA (see the list of ingredients in full Prescribing Information).

Please see additional Important Safety Information on the following pages, and full 

Prescribing Information, including Patient Information.

*People with impaired kidney function, asthma, and COPD participated in the SARCLISA study.

1


background image Sarclisa-PI-based-logo

Important Safety Information (cont’d)

Before receiving SARCLISA, tell your healthcare provider about all of your medical conditions, including if you:

     

are pregnant or plan to become pregnant. SARCLISA may harm your unborn baby. You should not receive 

SARCLISA during pregnancy. 
   Females who are able to become pregnant should use an effective method of birth control during treatment 

and for 5 months after their last dose of SARCLISA. Talk to your healthcare provider about birth control methods 

that you can use during this time.

   Tell your healthcare provider right away if you think you are pregnant or become pregnant during treatment 

with SARCLISA.

     

are breastfeeding or plan to breastfeed. It is not known if SARCLISA passes into your breast milk. You should not 

breastfeed during treatment with SARCLISA.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter 

medicines, vitamins, and herbal supplements.
How will I receive SARCLISA?

  

SARCLISA will be given to you by your healthcare provider by intravenous (IV) infusion into your vein.

  

SARCLISA is given in treatment cycles of 28 days (4 weeks), together with the medicines pomalidomide 

and dexamethasone.

   — In cycle 1, SARCLISA is usually given weekly.
   — Starting in cycle 2, SARCLISA is usually given every 2 weeks.
   Your healthcare provider will decide how long you should receive SARCLISA.

  

If you miss any appointments, call your healthcare provider as soon as possible to reschedule your appointment.

  

Your healthcare provider will give you medicines before each dose of SARCLISA to help reduce the risk of infusion 

reactions (make them less frequent and severe).

What are the possible side effects of SARCLISA?
SARCLISA may cause serious side effects, including:

  

Infusion reactions. Infusion reactions are common with SARCLISA and can sometimes be severe.

   — Your healthcare provider will prescribe medicines before each infusion of SARCLISA to help decrease your 

risk for infusion reactions or to help make any infusion reaction less severe. You will be monitored for infusion 

reactions during each dose of SARCLISA.

   — Your healthcare provider may slow down or stop your infusion, or completely stop treatment with SARCLISA, 

if you have an infusion reaction.

   Tell your healthcare provider right away if you develop any of the following symptoms of infusion 

reaction during or within 24 hours after an infusion of SARCLISA:

—  feeling short of breath

—   chills

—  cough

—   nausea

     

Decreased white blood cell counts. Decreased white blood cell counts are common with SARCLISA and 

certain white blood cells can be severely decreased. You may have an increased risk of getting certain 

infections, such as upper and lower respiratory infections. 
Your healthcare provider will check your blood cell counts during treatment with SARCLISA. Your healthcare 

provider may prescribe an antibiotic or antiviral medicine to help prevent infection, or a medicine to help 

increase your white blood cell counts during treatment with SARCLISA.

Please see additional Important Safety Information on the next page, 

and full Prescribing Information, including Patient Information

2


background image Sarclisa-PI-based-logo

Revlimid is a registered trademark of Celgene Corporation. 

© 2020 sanofi-aventis U.S. LLC.    All rights reserved.    MAT-US-2002028    07/20

Important Safety Information (cont’d)

   Tell your healthcare provider right away if you develop any fever or symptoms of infection during 

treatment with SARCLISA.

     

Risk of new cancers. New cancers have happened in people during treatment with SARCLISA. Your 

healthcare provider will monitor you for new cancers during treatment with SARCLISA.

     

Change in blood tests. SARCLISA can affect the results of blood tests to match your blood type. Your 

healthcare provider will do blood tests to match your blood type before you start treatment with SARCLISA.

 

   Tell all of your healthcare providers that you are being treated with SARCLISA before receiving 

   blood transfusions.
The most common side effects of SARCLISA include:  

     

lung infection (pneumonia)

     

decreased red blood cell counts (anemia) 

     

upper respiratory tract infection

     

decreased platelet counts (thrombocytopenia)

     

diarrhea 

These are not all the possible side effects of SARCLISA. For more information, ask your healthcare provider 

or pharmacist.

Please see full Prescribing Information, including Patient Information.

3


background image Sarclisa-PI-based-logo

Find out more by visiting SARCLISA.com.

Treatment with SARCLISA

• 

How will I receive treatment with SARCLISA?

  

• 

How will I know if SARCLISA is working?

• 

How will you monitor my results?

• 

What are the possible side effects?

Considering SARCLISA

• 

  

Is there a study that shows SARCLISA may work for my condition?

• 

Was SARCLISA studied in people like me?

• 

What were the study results for SARCLISA?

• 

Based on my treatment history, is SARCLISA an option for me?

• 

  

Is there a patient support program that may help with the cost of SARCLISA?

Talk with your doctor about SARCLISA

If you or your loved one is considering treatment with SARCLISA, the questions  

below can help you have a productive conversation with your doctor


background image

Notes and questions

Use this space to write down additional questions you may have 

or information you want to share with your doctor

New to SARCLISA® (isatuximab-irfc)?

Sign up for updates at SARCLISA.com to get the latest information.

Already signed up?

For information about our patient support program, CareASSIST from Sanofi Genzyme, 
please call 1-833-WE+CARE (1-833-930-2273), Mon – Fri, 9 am - 8 pm ET,

or visit SanofiCareAssist.com/sarclisa.

© 2020 sanofi-aventis U.S. LLC.     All rights reserved.     MAT-US-2004871     07/20